Skip to main content
Canna~Fangled Abstracts

Preparation of a nanoemulsion containing active ingredients of cannabis extract and its application for glioblastoma: in vitro and in vivo studies

By October 8, 2024No Comments

. 2024 Oct 7;25(1):73.

doi: 10.1186/s40360-024-00788-w.

Houra Mobaleghol Eslam 1, Fatemeh Hataminia 1, Fariba Esmaeili 1, Seyed Alireza Salami 2 3, Hossein Ghanbari 1 4, Amir Amani 5
Affiliations 

Free article

Abstract

Recently, the anti-tumor effects of cannabis extract on various cancers have attracted the attention of researchers. Here, we report a nanoemulsion (NE) composition designed to enhance the delivery of two active components in cannabis extracts (∆9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)) in an animal model of glioblastoma. The efficacy of the NE containing the two drugs (NED) was compared with the bulk drugs and carrier (NE without the drugs) using the C6 tumor model in rats. Hemocompatibility factors (RBC, MCV, MCH, MCHC, RDW, PPP, PT and PTT) were studied to determine the potential in vivo toxicity of NED. The optimized NED with mean ± SD diameter 29 ± 6 nm was obtained. It was shown that by administering the drugs in the form of NED, the hemocompatibility increased. Cytotoxicity studies indicated that the NE without the active components (i.e. mixture of surfactants and oil) was the most cytotoxic group, while the bulk group had no toxicity. From the in vivo MRI and survival studies, the NED group had maximum efficacy (with ~4 times smaller tumor volume on day 7 of treatment, compared with the control. Also, survival time of the control, bulk drug, NE and NED were 9, 4, 12.5 and 51 days, respectively) with no important adverse effects. In conclusion, the NE containing cannabis extract could be introduced as an effective treatment in reducing brain glioblastoma tumor progression.

Keywords: CBD, Glioblastoma, Hemocompatibility, In vivo model, Nanoemulsion, THC

PubMed Disclaimer

References

    1. Mathew EN, Berry BC, Yang HW, Carroll RS, Johnson MD. Delivering therapeutics to Glioblastoma: overcoming Biological constraints. Int J Mol Sci. 2022;23:1711. – DOI
    1. Bausart M, Préat V, Malfanti A. Immunotherapy for glioblastoma: the promise of combination strategies. J Experimental Clin Cancer Res. 2022;41:1–22. – DOI
    1. Lima FR, Kahn SA, Soletti RC, Biasoli D, Alves T, da Fonseca ACC, Garcia C, Romão L, Brito J, Holanda-Afonso R. Glioblastoma: therapeutic challenges, what lies ahead. Biochim et Biophys Acta (BBA)-Reviews Cancer. 2012;1826:338–49. – DOI
    1. Merlin MD. Archaeological evidence for the tradition of psychoactive plant use in the old world. Econ Bot. 2003;57:295–323. – DOI
    1. Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 2002;42:S11–9. – DOI

MeSH terms

Substances

LinkOut – more resources

Leave a Reply